Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
In this podcast episode, listen to Chris Parker, MD, and Bertrand Tombal, MD, PhD, as they discuss clinical implications of the latest data from ASCO 2021 on using radium-223, PSMA lutetium, and bone health approaches for the treatment and management of patients with metastatic castration-resistant prostate cancer.
Decera Clinical Education Oncology Podcast · Chris Parker MD, Bertrand Tombal MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:
- Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
- Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
- Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC
Presenters:
Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.